Organon & Co. (OGN) is a global healthcare company dedicated to improving women's health and delivering innovative health solutions. The company offers a diverse portfolio of prescription therapies and medical devices, focusing on women's health, biosimilars, and established brands. Organon operates worldwide, with a significant portion of its revenue generated outside the United States, and leverages its manufacturing facilities across multiple countries to distribute its products.
- Established Brands - Offers over 60 medicines across therapeutic areas such as cardiovascular, respiratory, dermatology, and non-opioid pain management, many of which have lost market exclusivity and face generic competition.
- Women’s Health - Focuses on contraception and fertility products, including Nexplanon (etonogestrel implant), NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), and Follistim AQ (follitropin beta injection). Also includes innovative devices like the Jada System for postpartum hemorrhage and Xaciato for bacterial vaginosis.
- Biosimilars - Develops and markets treatments for oncology and immunology, including products like Ontruzant (trastuzumab), Renflexis (infliximab-abda), and Hadlima (adalimumab-bwwd), with a growing presence in global markets.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Kevin Ali Executive | Chief Executive Officer (CEO) | None | CEO of Organon since its inception in 2021; previously held leadership roles at Merck, including President of Merck International and Emerging Markets. | View Report → |
Kirke Weaver Executive | EVP, General Counsel, and Corporate Secretary | None | General Counsel of Organon since 2021; played a key role in Organon's launch; previously held senior legal roles at Merck for 18 years. | |
Matthew Walsh Executive | Executive Vice President and CFO | Board Member at Certara, Inc. | CFO of Organon since 2021; previously EVP and CFO at Allergan and Catalent; extensive experience in financial leadership in the pharmaceutical industry. | |
Carrie S. Cox Board | Chairman of the Board | Chairman at Cartesian Therapeutics and Solventum Corporation; Director at Texas Instruments Inc. | Chairman of Organon’s Board since 2021; extensive executive experience in the pharmaceutical industry, including leadership roles at Humacyte, Schering-Plough, and Pharmacia. | |
Cynthia M. Patton Board | Independent Director | General Counsel and Corporate Secretary at Tessera Therapeutics; Trustee at Vassar College; Board Member at Martin Luther King, Jr. Community Hospital and Los Angeles Music Center | Director at Organon since 2021; legal and compliance expert with leadership experience at Verily Life Sciences and Amgen. | |
Deborah Leone Board | Independent Director | Director at Goldman Sachs Bank USA, Goldman Sachs Philanthropy Fund, Ayco Charitable Foundation; Trustee at Syracuse University; Director at Corebridge Financial, Inc. | Director at Organon since 2021; retired partner at Goldman Sachs with expertise in financial and operational leadership. | |
Grace Puma Board | Independent Director | Director at Target Corporation | Director at Organon since 2021; former EVP and COO at PepsiCo; extensive expertise in global procurement and supply chain management. | |
Helene Gayle, M.D. Board | Independent Director | President of Spelman College; Director at The Coca-Cola Company and Palo Alto Networks Inc. | Director at Organon since 2021; global health expert with leadership experience in public health and non-profit organizations; President of Spelman College. | |
Rochelle Lazarus Board | Independent Director | Chairman Emeritus of Ogilvy & Mather; Director at Blackstone, Inc. and Rockefeller Capital Management | Director at Organon since 2021; extensive experience in advertising and marketing; serves on multiple boards and charitable organizations. | |
Shalini Sharp Board | Independent Director | Director at Neurocrine Biosciences, Inc. | Director at Organon since 2021; financial expert with extensive experience in the biopharmaceutical industry, including CFO roles at Ultragenyx and Agenus. |
-
With the $180 million operating expense for Dermavant in 2025 primarily focused on launching VTAMA in atopic dermatitis , how confident are you in achieving the projected sales of at least $150 million , and what contingencies are in place if the launch underperforms?
-
Given that VTAMA's performance in the psoriasis market was limited, and you have high expectations for its potential in atopic dermatitis , what specific strategies will you employ to overcome the challenges faced in psoriasis and ensure success in this larger but competitive market?
-
You mentioned that the Dermavant acquisition will be dilutive to profitability in 2025 by about 0.5 percentage points of EBITDA margin , how do you plan to offset this dilution, and what measures are you taking to ensure it becomes accretive in 2026 and beyond?
-
The Fertility business is facing a softer outlook for the year, tempering down from a 9% volume growth rate to approximately 7% , could you elaborate on the factors contributing to this slowdown and how you plan to achieve the projected strong rebound in 2025?
-
With increasing competitive pressures and pricing headwinds in certain mature products such as NuvaRing, DULERA, and RENFLEXIS , how do you intend to mitigate these challenges to maintain your gross margin and overall profitability?
Research analysts who have asked questions during Organon & earnings calls.
Jason Gerberry
Bank of America Merrill Lynch
4 questions for OGN
Umer Raffat
Evercore ISI
4 questions for OGN
David Amsellem
Piper Sandler Companies
3 questions for OGN
Michael Nedelcovych
TD Cowen
3 questions for OGN
Balaji Prasad
Barclays
2 questions for OGN
Ethan Brown
JPMorgan Chase & Co.
2 questions for OGN
Terence Flynn
Morgan Stanley
2 questions for OGN
Alex Riesemann
Piper Sandler Companies
1 question for OGN
Chris Schott
JPMorgan Chase & Co.
1 question for OGN
| Customer | Relationship | Segment | Details |
|---|---|---|---|
McKesson | Major drug wholesaler | All | 12% of total gross A/R as of 12/31/2024 |
Cardinal Health | Major drug wholesaler | All | 7% of total gross A/R as of 12/31/2024 |
Cencora, Inc. | Major drug wholesaler | All | 6% of total gross A/R as of 12/31/2024 |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Dermavant Sciences Ltd. | 2024 | Completed acquisition where Organon executed a merger via its subsidiary with Dermavant, with total potential consideration of up to $1.2 billion (including an upfront payment of $175 million, milestone and commercial payments) to bolster its dermatology portfolio with VTAMA® (tapinarof) cream, subject to FDA approval and regulatory conditions. |
Claria Medical, Inc. | 2023 | Planned acquisition/investment via a strategic investment, involving an $8 million upfront payment with an option to acquire the company for an additional $47 million based on milestones, intended to develop an investigational device for minimally invasive laparoscopic hysterectomy. |
Bayer AG (Product rights for Marvelon™ and Mercilon™) | 2022 | Completed asset acquisition of the product rights and related inventory for Marvelon™ and Mercilon™, executed in stages across 2022 with payments of $30 million (plus $35 million subsequently) for China and $30 million for Vietnam, thereby expanding Organon’s prescription contraceptive portfolio in key Asian markets. |
Recent press releases and 8-K filings for OGN.
- Law Offices of Howard G. Smith reminds investors of a class action lawsuit filed against Organon & Co. (NYSE: OGN).
- The class period for the lawsuit is November 3, 2022 – April 30, 2025, with the lead plaintiff deadline set for July 22, 2025.
- The complaint alleges that Organon's optimistic reports regarding dividend payouts were misleading due to a newly implemented debt reduction strategy, which resulted in a drastic decrease of over 70% in the quarterly dividend. It also alleges that Organon planned to prioritize debt reduction following the acquisition of Dermavant.
- Faruqi & Faruqi, LLP is investigating Organon & Co. (NYSE: OGN) for a federal securities class action lawsuit, with a deadline for investors to seek the role of lead plaintiff by July 22, 2025.
- The lawsuit alleges Organon made materially false and misleading statements and/or concealed material adverse facts concerning its capital allocation strategy, particularly regarding quarterly dividends, while prioritizing debt reduction after the Dermavant acquisition.
- This alleged misconduct led to a 70% decrease in the regular quarterly dividend.
- Following these revelations, Organon's stock price declined by more than 27%, falling from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025.
- Investors who purchased or acquired Organon securities between November 3, 2022, and April 30, 2025, and suffered losses are encouraged to contact the law firm.
- A class action lawsuit has been filed against Organon & Co. (NYSE: OGN) for investors who purchased securities between November 3, 2022 and April 30, 2025.
- The lawsuit alleges that Organon concealed its debt reduction strategy, which conflicted with maintaining its dividend, despite public statements prioritizing the dividend.
- This strategy, particularly after the acquisition of Dermavant Sciences Ltd., led to a substantial dividend cut from $0.28 to $0.02 per share announced on May 1, 2025, causing Organon's stock to decline more than 27%.
- The deadline for investors to file a lead plaintiff motion is July 22, 2025.
- A class action lawsuit has been filed against Organon & Co. (NYSE: OGN) on behalf of investors who purchased securities between November 3, 2022, and April 30, 2025.
- Investors have until July 22, 2025, to file a lead plaintiff motion in the class action.
- The lawsuit alleges that Organon concealed information about its capital allocation strategy, specifically its plans for quarterly dividend payouts, and adopted a debt reduction strategy that conflicted with maintaining the dividend despite public statements.
- Following the acquisition of Dermavant Sciences Ltd., Organon allegedly intended to shift capital priorities towards debt reduction, leading to a substantial dividend cut. On May 1, 2025, Organon announced a reduction in its quarterly dividend from $0.28 to $0.02 per share, which led to a stock decline of more than 27%.
- A class action lawsuit has been filed against Organon & Co. (NYSE: OGN) on behalf of its shareholders.
- The lawsuit covers a Class Period from November 3, 2022, to April 30, 2025, with a Lead Plaintiff Deadline of July 22, 2025.
- The complaint alleges that Organon made misleading statements regarding its dividend payout, which drastically decreased by over 70% due to a new debt reduction strategy following the acquisition of Dermavant.
- Triple Flag Precious Metals (TFPM) has completed the strategic acquisition of Orogen Royalties for approximately C$421 million.
- The acquisition significantly enhances Triple Flag's portfolio by adding a 1.0% net smelter returns (NSR) royalty on the Arthur gold project in Nevada.
- The transaction involved a combination of C$171.5 million in cash and the issuance of 5,633,629 Triple Flag common shares to Orogen shareholders.
- This acquisition contributed to Triple Flag's record quarterly revenues of $94.1 million and establishes a generative exploration alliance for future growth.
- Organon & Co. (NYSE: OGN) is facing a class action lawsuit on behalf of investors who purchased securities between October 31, 2024, and April 30, 2025.
- The lawsuit alleges that Organon concealed its debt reduction strategy, which conflicted with maintaining its dividend, despite public statements prioritizing dividend payouts.
- On May 1, 2025, Organon announced a sharp quarterly dividend reduction from $0.28 to $0.02 per share, which resulted in a stock decline of more than 27%.
- Investors have until July 22, 2025, to file a lead plaintiff motion.
- Organon's VTAMA (tapinarof) cream, 1%, received a strong recommendation from the American Academy of Dermatology (AAD) in their 2025 updated guidelines for adults with moderate to severe atopic dermatitis (AD).
- This recommendation highlights VTAMA cream as an effective, steroid-free topical treatment with no label warnings, contraindications, or restrictions on duration of use or body surface area.
- VTAMA cream was approved by the FDA for the topical treatment of AD in adults and pediatric patients 2 years and older in December 2024.
- The ADORING 3 study indicated a potential treatment-free interval averaging 80 days after treatment success, which could redefine AD treatment.
- Multiple law firms filed securities class action lawsuits against Organon on behalf of investors who bought its securities between October 31, 2024 and April 30, 2025, alleging misleading statements on capital allocation priorities.
- The suits contend Organon assured dividends were a top priority but cut its quarterly dividend by over 70%, prompting a 27% stock price drop of $3.48 to $9.45 on May 1, 2025.
- Affected investors have until July 22, 2025 to file lead plaintiff motions to seek recovery for losses suffered during the class period.
- The litigation highlights concerns over Organon’s transparency and post-acquisition financial management following its Dermavant purchase.
- Participating investors incur no out-of-pocket costs under the contingency fee arrangements offered by the law firms.
- Quorum confirmed: The meeting confirmed a quorum with 82.81% of the voting power (over 250 million shares represented) on record as of 04/14/2025.
- Key proposals approved: Director nominees, the nonbinding advisory vote on executive compensation, the amendment of the incentive stock plan, and the auditor ratification were approved, while the director election resignation guideline proposal received only 20.9% affirmative votes, not meeting the majority requirement.
- Broad shareholder participation: The AGM, held on June 10, 2025, saw active participation via proxy and online ballots ensuring that all proposals were duly voted on.